Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Development and preliminary validation of an LC-MS/MS method for sunitinib therapeutic drug monitoring using quantitative dried blood spots with a blood-to-plasma conversion formula.

Created on 13 Nov 2026

Authors

Qiaoqiao Li, Maocai Tang, Tiantian Tang, Jin Zeng, Min Zhang, Xiaoxiao Wang, Wanyi Chen, Lixian Li

Published in

Clinical biochemistry. Pages 111222. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Conventional venous sampling cannot reliably ensure accurate collection timing, potentially affecting therapeutic drug monitoring (TDM) of sunitinib (SUN). Quantitative dried blood spot (qDBS) sampling offers a patient-centric alternative; however, reliable DBS-to-plasma conversion requires validation. This study therefore aims to develop and preliminarily validate a qDBS-to-plasma conversion formula for SUN TDM.
A qDBS based method was developed and validated for simultaneous quantification of SUN and its active metabolite N-desethyl sunitinib (SU12662). Analytical validation followed FDA and IATDMCT guidelines. The impact of hematocrit (Hct) on quantification was evaluated. Thirty-eight paired DBS and plasma samples were concentration-stratified and randomly divided into a derivation set (n = 20) and a validation set (n = 18). Passing-Bablok regression was used to establish conversion equations, which were evaluated by Bland-Altman analysis and the EMA ±20% acceptance criterion.
The method demonstrated satisfactory analytical performance. Hct-related bias was negligible within 30%-50%, supporting conversion without additional Hct correction. Passing-Bablok regression generated the conversion equations: CDBS = -3.61 + 1.69 × Cpla for SUN and CDBS = -1.42 + 1.70 × Cpla for SU12662. In the validation set, Bland-Altman analysis showed minimal bias between estimated and measured plasma concentrations (SUN: -0.91%; SU12662: 4.58%). The EMA ±20% criterion was met for 14/18 SUN samples (77.8%) and 18/18 SU12662 samples (100%).
This study developed and preliminarily validated a qDBS-based conversion strategy for SUN TDM. The minimal Hct effect and acceptable agreement in the validation set support further evaluation of qDBS for patient-centric SUN TDM.

PMID:
43020305
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement